UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 39

Sortiert nach

Single- and Multiple-Dose Study To Determine the Safety, Tolerability, Pharmacokinetics, and Food Effect of Oral MRX-I versus Linezolid in Healthy Adult Subjects

Antimicrobial agents and chemotherapy, 2017-04, Vol.61 (4)

2017

Volltextzugriff (PDF)

Linezolid versus Vancomycin for the Treatment of Methicillin-Resistant Staphylococcus aureus Infections

Clinical infectious diseases, 2002-06, Vol.34 (11), p.1481-1490

2002

Volltextzugriff (PDF)

Mode of Action, In Vitro Activity, and In Vivo Efficacy of AFN-1252, a Selective Antistaphylococcal FabI Inhibitor

Antimicrobial Agents and Chemotherapy, 2012-11, Vol.56 (11), p.5865-5874

2012

Volltextzugriff (PDF)

AFN-1252, a FabI Inhibitor, Demonstrates a Staphylococcus-Specific Spectrum of Activity

Antimicrobial Agents and Chemotherapy, 2009-08, Vol.53 (8), p.3544-3548

2009

Volltextzugriff (PDF)

Hematologic Effects of Linezolid: Summary of Clinical Experience

Antimicrobial Agents and Chemotherapy, 2002-08, Vol.46 (8), p.2723-2726

2002

Volltextzugriff (PDF)

Worldwide Assessment of Linezolid's Clinical Safety and Tolerability: Comparator-Controlled Phase III Studies

Antimicrobial Agents and Chemotherapy, 2003-06, Vol.47 (6), p.1824-1831

2003

Volltextzugriff (PDF)

Randomized Comparison of Linezolid (PNU-100766) versus Oxacillin-Dicloxacillin for Treatment of Complicated Skin and Soft Tissue Infections

Antimicrobial Agents and Chemotherapy, 2000-12, Vol.44 (12), p.3408-3413

2000

Volltextzugriff (PDF)

In Vitro and In Vivo Activities of Contezolid (MRX-I) against Mycobacterium tuberculosis

Antimicrobial agents and chemotherapy, 2018-08, Vol.62 (8)

2018

Volltextzugriff (PDF)

AFN-1252 in vitro absorption studies and pharmacokinetics following microdosing in healthy subjects

European journal of pharmaceutical sciences, 2013-11, Vol.50 (3-4), p.440-446

2013

Volltextzugriff (PDF)

1118. Population Pharmacokinetics of Contezolid Acefosamil and Contezolid – Rationale for a Safe and Effective Loading Dose Regimen

Open forum infectious diseases, 2021-12, Vol.8 (Supplement_1), p.S651-S651

2021

Volltextzugriff (PDF)

Contezolid can replace linezolid in a novel combination with bedaquiline and pretomanid in a murine model of tuberculosis

Antimicrobial agents and chemotherapy, 2023-12, Vol.67 (12), p.e0078923-e0078923

2023

Volltextzugriff (PDF)

Population pharmacokinetic rationale for intravenous contezolid acefosamil followed by oral contezolid dosage regimens

Antimicrobial agents and chemotherapy, 2024-04, Vol.68 (4), p.e0140023

2024

Volltextzugriff (PDF)

Safety, tolerability and pharmacokinetics of multiple oral doses of AFN-1252 administered as immediate release (IR) tablets in healthy subjects

Journal of chemotherapy (Florence), 2016-05, Vol.28 (3), p.164-171

2016

Volltextzugriff (PDF)

Safety, tolerability and pharmacokinetics of AFN-1252 administered as immediate release tablets in healthy subjects

Future microbiology, 2015-11, Vol.10 (11), p.1805-1813

2015

Volltextzugriff (PDF)

Corrigendum to “AFN-1252 in vitro absorption studies and pharmacokinetics following” [Eur. J. Pharm. 50 (3–4) (2013) 440–446]

European journal of pharmaceutical sciences, 2014-02, Vol.52, p.223-223

2014

Volltextzugriff (PDF)

Pharmacokinetics, pharmacodynamics and efficacy of novel FabI inhibitor AFN-1252 against MSSA and MRSA in the murine thigh infection model

Journal of chemotherapy (Florence), 2013-02, Vol.25 (1), p.26-31

2013

Volltextzugriff (PDF)

In vitro activity (MICs and rate of kill) of AFN-1252, a novel FabI inhibitor, in the presence of serum and in combination with other antibiotics

Journal of chemotherapy (Florence), 2013-02, Vol.25 (1), p.18-25

2013

Volltextzugriff (PDF)

Pharmacokinetics, pharmacodynamics and efficacy of novel Fabl inhibitor AFN-1252 against MSSA and MRSA in the murine thigh infection model

Journal of chemotherapy (Florence), 2013, Vol.25 (1), p.26-31

2013

Volltextzugriff (PDF)

Single-Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a FabI Inhibitor, the Prodrug Debio 1450 and Its Active Moiety Debio 1452, Administered Intravenously in Healthy Subjects

Open forum infectious diseases, 2015-12, Vol.2 (suppl_1)

2015

Volltextzugriff (PDF)

In vitro activity (MICs and rate of kill) of AFN-1252, a novel Fabl inhibitor, in the presence of serum and in combination with other antibiotics

Journal of chemotherapy (Florence), 2013, Vol.25 (1), p.18-25

2013

Volltextzugriff (PDF)

797Single-Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a FabI Inhibitor, the Prodrug Debio 1450 and Its Active Moiety Debio 1452, Administered Intravenously in Healthy Subjects

Open forum infectious diseases, 2015-12, Vol.2 (suppl_1), p.S232-S232

2015

Volltextzugriff (PDF)

Comparison of Length of Hospital Stay for Patients with Known or Suspected Methicillin-Resistant Staphylococcus Species Infections Treated with Linezolid or Vancomycin: A Randomized, Multicenter Trial

Pharmacotherapy, 2001-03, Vol.21 (3), p.263-274

2001

Volltextzugriff (PDF)

Effects of food and sucralfate on a single oral dose of 500 milligrams of levofloxacin in healthy subjects

Antimicrobial Agents and Chemotherapy, 1997-10, Vol.41 (10), p.2196-2200

1997

Volltextzugriff (PDF)

MK-386, an inhibitor of 5α-reductase type 1, reduces dihydrotestosterone concentrations in serum and sebum without affecting dihydrotestosterone concentrations in semen

The journal of clinical endocrinology and metabolism, 1997, Vol.82 (5), p.1373-1377

1997

Volltextzugriff (PDF)

LINEZOLID ACTIVITY AGAINST PENICILLIN-INTERMEDIATE AND RESISTANT STREPTOCOCCUS PNEUMONIAE IN PATIENTS WITH PNEUMONIA

Chest, 2000-10, Vol.118 (4), p.243

2000

Volltextzugriff (PDF)

1 – 25 von 39

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(39)
Mit Volltextzugriff
(25)

Publikationsform

Artikel
(39)

Sprache

Englisch
(39)
Japanisch
(4)

Erscheinungsjahr

n.n

Thema

Humans
(22)
Life Sciences & Biomedicine
(22)
Science & Technology
(22)
Male
(18)
Adult
(16)
Pharmacology & Pharmacy
(16)
Biological And Medical Sciences
(15)
Medical Sciences
(15)
Female
(14)
Pharmacology. Drug Treatments
(13)
Microbiology
(12)
Antibiotics. Antiinfectious Agents. Antiparasitic Agents
(10)
Adolescent
(9)
Middle Aged
(8)
Animals
(7)
Antibacterial Agents
(7)
Infectious Diseases
(7)
Linezolid
(7)
Oxazolidinones
(7)
Staphylococcus Aureus
(7)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Single- and Multiple-Dose Study To Determine the Safety, Tolerability, Pharmacokinetics, and Food Effect of Oral MRX-I versus Linezolid in Healthy Adult Subjects

Linezolid versus Vancomycin for the Treatment of Methicillin-Resistant Staphylococcus aureus Infections

Mode of Action, In Vitro Activity, and In Vivo Efficacy of AFN-1252, a Selective Antistaphylococcal FabI Inhibitor

AFN-1252, a FabI Inhibitor, Demonstrates a Staphylococcus-Specific Spectrum of Activity

Hematologic Effects of Linezolid: Summary of Clinical Experience

Worldwide Assessment of Linezolid's Clinical Safety and Tolerability: Comparator-Controlled Phase III Studies

Randomized Comparison of Linezolid (PNU-100766) versus Oxacillin-Dicloxacillin for Treatment of Complicated Skin and Soft Tissue Infections

In Vitro and In Vivo Activities of Contezolid (MRX-I) against Mycobacterium tuberculosis

AFN-1252 in vitro absorption studies and pharmacokinetics following microdosing in healthy subjects

1118. Population Pharmacokinetics of Contezolid Acefosamil and Contezolid – Rationale for a Safe and Effective Loading Dose Regimen

Contezolid can replace linezolid in a novel combination with bedaquiline and pretomanid in a murine model of tuberculosis

Population pharmacokinetic rationale for intravenous contezolid acefosamil followed by oral contezolid dosage regimens

Safety, tolerability and pharmacokinetics of multiple oral doses of AFN-1252 administered as immediate release (IR) tablets in healthy subjects

Safety, tolerability and pharmacokinetics of AFN-1252 administered as immediate release tablets in healthy subjects

Corrigendum to “AFN-1252 in vitro absorption studies and pharmacokinetics following” [Eur. J. Pharm. 50 (3–4) (2013) 440–446]

Pharmacokinetics, pharmacodynamics and efficacy of novel FabI inhibitor AFN-1252 against MSSA and MRSA in the murine thigh infection model

In vitro activity (MICs and rate of kill) of AFN-1252, a novel FabI inhibitor, in the presence of serum and in combination with other antibiotics

Pharmacokinetics, pharmacodynamics and efficacy of novel Fabl inhibitor AFN-1252 against MSSA and MRSA in the murine thigh infection model

Single-Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a FabI Inhibitor, the Prodrug Debio 1450 and Its Active Moiety Debio 1452, Administered Intravenously in Healthy Subjects

In vitro activity (MICs and rate of kill) of AFN-1252, a novel Fabl inhibitor, in the presence of serum and in combination with other antibiotics

797Single-Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a FabI Inhibitor, the Prodrug Debio 1450 and Its Active Moiety Debio 1452, Administered Intravenously in Healthy Subjects

Comparison of Length of Hospital Stay for Patients with Known or Suspected Methicillin-Resistant Staphylococcus Species Infections Treated with Linezolid or Vancomycin: A Randomized, Multicenter Trial

Effects of food and sucralfate on a single oral dose of 500 milligrams of levofloxacin in healthy subjects

MK-386, an inhibitor of 5α-reductase type 1, reduces dihydrotestosterone concentrations in serum and sebum without affecting dihydrotestosterone concentrations in semen

LINEZOLID ACTIVITY AGAINST PENICILLIN-INTERMEDIATE AND RESISTANT STREPTOCOCCUS PNEUMONIAE IN PATIENTS WITH PNEUMONIA

Suchergebnisse filtern